RE:RE:CashThe MD&A says they have 12-24 months cash. The pediatric diagnostic trial is over. They have discontinued development of AEZS's pipeline. They can license the diagnostic in the US given it is already approved in the US for adults.CSCI has enough cash to reach a proof of principle for the avenanthramide pill trial through the Phase I/IIa clinical trial. The 5X PGX scale-up has been completed and can be launched commercially at smal-scale. The 10X PGX commissioning is scheduled to be completed in Q1 and is the decision point for mass industrialization.
The company has the tax loss carryforwards from the merger as it works out it plans. The forward plan for the diagnostic is still being deveeloped. Will they sell the pipeline products from AEZS that they don't have the cash for given the unfortunate developments with regards to the pediatric diagnostic trial for additional cash? Trump may change regulatory requirements too for the drug approval process.
Tencents wrote: Alterna had 38 m cash end September 2023
burning about 5 m per qtr this will be zero end march 2025
czs had 12 m cash end September 2023. It's about break even since then
so the cash position early 2025 will be about 12 m
its 20 today with 4 m per quarter being eaten
this brings us back to the original position of czs pre merger
same cash and same projets